Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06098612 · ClinicalTrials.gov registry record · Early Phase 1
PET Imaging Evaluation of [11C]SY08
A Early Phase 1 study of Parkinson's Disease and Multiple System Atrophy, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06098612 is a Early Phase 1 study of Parkinson's Disease and Multiple System Atrophy that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 40 participants, below the 639-participant average among 157 other Parkinson's Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06098612, a Early Phase 1 study of Parkinson's Disease and Multiple System Atrophy, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls. The specific aims of the current study are: 1. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in healthy individuals. 2. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in patients with alpha synuclein aggregates in the brain, including PD, DLB and MSA. 3. To determine human dosimetry of \[11C\]SY08 in healthy individuals An intravenous bolus injection of \[11C\]SY08 will be administered per subject for brain PET imaging.
Conditions Studied
Interventions
- DRUG C11-SY08
Study Locations (1)
Massachusetts
- MGH - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2027-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06098612
The ClinicalTrials.gov registry entry for NCT06098612 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 639-participant average among 157 other Parkinson's Disease trials with a reported enrollment target (94% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which C11-SY08 is the first listed.
NCT06098612 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06098612 about?
NCT06098612 is a clinical study titled "PET Imaging Evaluation of [11C]SY08". The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to...
What is the current status of trial NCT06098612?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2024-05-01. Estimated completion is 2027-11.
What conditions does trial NCT06098612 study?
This clinical trial studies the following conditions: Parkinson's Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Healthy (Controls).
What interventions are being tested in trial NCT06098612?
The interventions under investigation include: C11-SY08 (DRUG).
Who is sponsoring clinical trial NCT06098612?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06098612 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
RECRUITING · Early Phase 1
-
Subthalamic Deep Brain Stimulation (DBS) in Parkinson's Disease
COMPLETED · Early Phase 1
-
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
RECRUITING · NA
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
Deep Brain Stimulation for Visuomotor Function in Parkinson's Disease
RECRUITING
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.